Featured

Status

All Statuses
  • Completed41

Health Topics

Any Category
Chemicals and Drugs
Heterocyclic Compounds
Clear Filters

Search Clinical Trials

41 Results
Completed
Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep
Alcohol is one of the most popular substances used worldwide for thousands of years. Globally, harmful alcohol use continues to be a major public health and economic burden. The World …
Baylor Role: Lead Sponsor
Completed
Acceptability and Performance of a Mobile Optical Biopsy Technology for Gastrointestinal Cancer Screening
The investigators' hypothesis is that this mobile device with automated, AR optical biopsy diagnoses can efficiently and accurately facilitate endoscopic cancer detection in low to middle income countries (LMICs) with …
Baylor Role: Collaborator
Completed
The Effectiveness of High Resolution Microendoscopy for People Living With HIV
The investigators' central hypothesis is that using mHRME plus 3D mapping as a diagnostic tool will improve the accuracy and efficiency of HSIL diagnoses. Additionally, the investigators hypothesize that the …
Baylor Role: Lead Sponsor
Completed
Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)
A maximum of 30 subjects will participate in the treatment part of this study. Up to 180ml of blood is collected from patients to grow the T cells. The T …
Baylor Role: Lead Sponsor
Completed
High-Risk Neuroblastoma Chemotherapy Without G-CSF
Chemotherapy: CYCLE 1+2: Topotecan and cyclophosphamide Cycle 3+5: Cisplatin and Etoposide Cycle 4+6: Vincristine, Cyclophosphamide and Doxorubicin Stem cell collection: After the third cycle of chemotherapy, stem cells will be …
Baylor Role: Lead Sponsor
Completed
Complementary Combination Therapy for Cocaine Dependence
During a screening session participants will provide buccal swab for genetics testing, as preliminary data shows that effects of cocaine and of doxazosin are impacted significantly by the genotype at …
Baylor Role: Lead Sponsor
Completed
Ceftaroline for Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in Children
This is a Phase 1/2, open-label, single-center study to determine safety and tolerability of Ceftaroline in pediatric subjects 1 to 17 years of age (inclusive) with signs and symptoms of …
Baylor Role: Lead Sponsor
Completed
Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)
The primary objective is to investigate whether all doses (0.1 mg/kg, 0.2 mg/kg, 0.5 mg/kg, and 1.0 mg/kg) of ketamine are superior to active placebo (midazolam 0.045 mg/kg) therapy in …
Baylor Role: Collaborator
Completed
Pharmacogenetic Trial of Doxazosin for Treatment of Cocaine Abuse
The noradrenergic system, especially the alpha 1-adrenergic receptor, may play an important role in cocaine addiction in humans. Doxazosin is a long-acting and selective alpha 1-adrenergic receptor blocker, which inhibits …
Baylor Role: Collaborator
Completed
Individualized High Dose Methotrexate to Treat Cancer in Children Who Have a Significant Risk for Side Effects to Methotrexate
The study participant will receive the drug methotrexate as a patient in the hospital. High dose methotrexate will be given as a 24-hour infusion as part of the care determined …
Baylor Role: Lead Sponsor